Literature DB >> 33470098

Discovery of Molecular Interactions of the Human Melanocortin-4 Receptor (hMC4R) Asp189 (D189) Amino Acid with the Endogenous G-Protein-Coupled Receptor (GPCR) Antagonist Agouti-Related Protein (AGRP) Provides Insights to AGRP's Inverse Agonist Pharmacology at the hMC4R.

Mark D Ericson1, Erica M Haslach2, Sathya M Schnell1, Katie T Freeman1, Zhimin M Xiang2, Frederico P Portillo2, Robert Speth3,4, Sally A Litherland5, Carrie Haskell-Luevano1,2.   

Abstract

The melanocortin receptors (MCRs) are important for numerous biological pathways, including feeding behavior and energy homeostasis. In addition to endogenous peptide agonists, this receptor family has two naturally occurring endogenous antagonists, agouti and agouti-related protein (AGRP). At the melanocortin-4 receptor (MC4R), the AGRP ligand functions as an endogenous inverse agonist in the absence of agonist and as a competitive antagonist in the presence of agonist. At the melanocortin-3 receptor (MC3R), AGRP functions solely as a competitive antagonist in the presence of agonist. The molecular interactions that differentiate AGRP's inverse agonist activity at the MC4R have remained elusive until the findings reported herein. Upon the basis of homology molecular modeling approaches, we previously postulated a unique interaction between the D189 position of the hMC4R and Asn114 of AGRP. To further test this hypothesis, six D189 mutant hMC4Rs (D189A, D189E, D189N, D189Q, D189S, and D189K) were generated and pharmacologically characterized resulting in the discovery of differences in inverse agonist activity of AGRP and an 11 macrocyclic compound library. These data support the hypothesized interaction between the hMC4R D189 position and Asn114 residue of AGRP and define critical ligand-receptor molecular interactions responsible for the inverse agonist activity of AGRP at the hMC4R.

Entities:  

Keywords:  Macrocyclic peptide; inverse agonism; mutant hMC4R

Mesh:

Substances:

Year:  2021        PMID: 33470098      PMCID: PMC7951137          DOI: 10.1021/acschemneuro.0c00755

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  65 in total

1.  Determination of the melanocortin-4 receptor structure identifies Ca2+ as a cofactor for ligand binding.

Authors:  Jing Yu; Luis E Gimenez; Ciria C Hernandez; Yiran Wu; Ariel H Wein; Gye Won Han; Kyle McClary; Sanraj R Mittal; Kylie Burdsall; Benjamin Stauch; Lijie Wu; Sophia N Stevens; Alys Peisley; Savannah Y Williams; Valerie Chen; Glenn L Millhauser; Suwen Zhao; Roger D Cone; Raymond C Stevens
Journal:  Science       Date:  2020-04-24       Impact factor: 47.728

2.  Targeted disruption of the melanocortin-4 receptor results in obesity in mice.

Authors:  D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

3.  Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice.

Authors:  Katlyn A Fleming; Mark D Ericson; Katie T Freeman; Danielle N Adank; Mary M Lunzer; Stacey L Wilber; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-02-13       Impact factor: 4.418

4.  Structure-Activity Relationship Studies on a Macrocyclic Agouti-Related Protein (AGRP) Scaffold Reveal Agouti Signaling Protein (ASP) Residue Substitutions Maintain Melanocortin-4 Receptor Antagonist Potency and Result in Inverse Agonist Pharmacology at the Melanocortin-5 Receptor.

Authors:  Mark D Ericson; Katie T Freeman; Sathya M Schnell; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2017-10-04       Impact factor: 7.446

5.  Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice.

Authors:  J R Shutter; M Graham; A C Kinsey; S Scully; R Lüthy; K L Stark
Journal:  Genes Dev       Date:  1997-03-01       Impact factor: 11.361

6.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

7.  The cloning of a family of genes that encode the melanocortin receptors.

Authors:  K G Mountjoy; L S Robbins; M T Mortrud; R D Cone
Journal:  Science       Date:  1992-08-28       Impact factor: 47.728

8.  Contribution of melanocortin receptor exoloops to Agouti-related protein binding.

Authors:  Y K Yang; C J Dickinson; Q Zeng; J Y Li; D A Thompson; I Gantz
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

9.  Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity.

Authors:  Pilgrim J Jackson; Joseph C McNulty; Ying-Kui Yang; Darren A Thompson; Biaoxin Chai; Ira Gantz; Gregory S Barsh; Glenn L Millhauser
Journal:  Biochemistry       Date:  2002-06-18       Impact factor: 3.162

10.  Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSH.

Authors:  Kathryn L Chapman; Gemma K Kinsella; Alan Cox; Dan Donnelly; John B C Findlay
Journal:  J Mol Biol       Date:  2010-06-19       Impact factor: 5.469

View more
  1 in total

1.  Functional Mixture-Based Positional Scan Identifies a Library of Antagonist Tetrapeptide Sequences (LAtTeS) with Nanomolar Potency for the Melanocortin-4 Receptor and Equipotent with the Endogenous AGRP(86-132) Antagonist.

Authors:  Mark D Ericson; Skye R Doering; Courtney M Larson; Katie T Freeman; Travis M LaVoi; Haley M Donow; Radleigh G Santos; Rachel H Cho; Zoe M Koerperich; Marc A Giulianotti; Clemencia Pinilla; Richard A Houghten; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2021-09-30       Impact factor: 8.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.